{"id":1219,"date":"2025-10-21T21:32:43","date_gmt":"2025-10-21T19:32:43","guid":{"rendered":"https:\/\/lensounds.com\/technologie\/"},"modified":"2026-03-31T13:42:21","modified_gmt":"2026-03-31T11:42:21","slug":"technology","status":"publish","type":"page","link":"https:\/\/atonco-pharma.com\/en\/technology\/","title":{"rendered":"Technology"},"content":{"rendered":"<!-- HERO COVER SECTION -->\n\n<div class=\"wp-block-cover atonco-hero\" style=\"padding-top:180px;padding-right:2rem;padding-bottom:60px;padding-left:2rem;min-height:420px\">\n  <span aria-hidden=\"true\" class=\"wp-block-cover__background has-black-background-color has-background-dim-30 has-background-dim\"><\/span>\n  <img decoding=\"async\" class=\"wp-block-cover__image-background\" alt=\"\" src=\"https:\/\/atonco-pharma.com\/wp-content\/uploads\/2025\/10\/contact2.jpg\" data-object-fit=\"cover\"\/>\n  \n  <div class=\"wp-block-cover__inner-container is-layout-flow wp-block-cover-is-layout-flow\">\n    \n    <div class=\"wp-block-group has-global-padding is-layout-constrained wp-container-core-group-is-layout-530ec779 wp-block-group-is-layout-constrained\">\n      \n      \n      <h1 class=\"wp-block-heading has-white-color has-text-color\" style=\"margin-bottom:16px;font-size:clamp(36px,4.5vw,54px);font-weight:800;line-height:1.1\">Technology<\/h1>\n      \n      \n      \n      <p class=\"has-text-color\" style=\"color:#eaf1f8;margin-top:0;margin-bottom:0;font-size:20px\">A disruptive innovation in the treatment of microscopic residual disease<\/p>\n      \n      \n    <\/div>\n    \n  <\/div>\n<\/div>\n\n\n<!-- NAVIGATION SUB-MENU -->\n\n<style>\n:root {\n  --atonco-primary: #3167ff;\n  --atonco-secondary: #3ae06a;\n  --atonco-ink: #0d2a3a;\n  --atonco-muted: #4c6678;\n  --atonco-card: #f0f4ff;\n  --atonco-bg: #ffffff;\n  --atonco-border: #b9d0ff;\n  --atonco-radius: 18px;\n  --atonco-shadow-soft: 0 10px 28px rgba(49,103,255,.14), 0 4px 14px rgba(13,42,58,.06);\n  --atonco-shadow-card: 0 18px 52px rgba(49,103,255,.10), 0 6px 18px rgba(13,42,58,.08);\n}\n\n.atonco-hero {\n  position: relative;\n  overflow: hidden;\n}\n\n.atonco-hero:before {\n  content: \"\";\n  position: absolute;\n  inset: 0;\n  background-image:\n    linear-gradient(to right, rgba(255,255,255,.05) 1px, transparent 1px),\n    linear-gradient(to bottom, rgba(255,255,255,.05) 1px, transparent 1px);\n  background-size: 36px 36px;\n  mask-image: linear-gradient(to bottom, black 20%, transparent 100%);\n  pointer-events: none;\n  z-index: 1;\n}\n\n.atonco-submenu-nav {\n  position: sticky;\n  top: 0;\n  z-index: 100;\n  background: #ffffff;\n  border-bottom: 2px solid var(--atonco-border);\n  box-shadow: var(--atonco-shadow-soft);\n}\n\n.atonco-submenu-nav .nav-container {\n  max-width: 1280px;\n  margin: 0 auto;\n  padding: 0 2rem;\n  display: flex;\n  gap: 1rem;\n}\n\n.atonco-submenu-nav button {\n  flex: 1;\n  padding: 1.25rem 2rem;\n  background: transparent;\n  border: none;\n  border-bottom: 3px solid transparent;\n  border-radius: var(--atonco-radius) var(--atonco-radius) 0 0;\n  font-size: 16px;\n  font-weight: 600;\n  color: var(--atonco-muted);\n  cursor: pointer;\n  transition: all 0.3s ease;\n  text-transform: none;\n  letter-spacing: normal;\n}\n\n.atonco-submenu-nav button:hover {\n  color: var(--atonco-primary);\n  background: rgba(49,103,255, 0.05);\n}\n\n.atonco-submenu-nav button.active {\n  color: var(--atonco-primary);\n  border-bottom: 3px solid;\n  border-image: linear-gradient(90deg, var(--atonco-primary) 0%, #414d93 35%, var(--atonco-secondary) 70%, var(--atonco-primary) 100%) 1;\n  background: rgba(49,103,255, 0.08);\n}\n\n.atonco-tab-content {\n  display: none;\n}\n\n.atonco-tab-content.active {\n  display: block;\n  animation: fadeIn 0.4s ease-in;\n}\n\n@keyframes fadeIn {\n  from { opacity: 0; transform: translateY(10px); }\n  to { opacity: 1; transform: translateY(0); }\n}\n\n@media (max-width: 768px) {\n  .atonco-submenu-nav .nav-container {\n    flex-direction: column;\n    padding: 0;\n    gap: 0;\n  }\n\n  .atonco-submenu-nav button {\n    padding: 1rem 1.5rem;\n    font-size: 14px;\n    border-bottom: 1px solid var(--atonco-border);\n    border-radius: 0;\n  }\n\n  .atonco-submenu-nav button.active {\n    border-left: 4px solid;\n    border-image: linear-gradient(180deg, var(--atonco-primary) 0%, #414d93 35%, var(--atonco-secondary) 70%, var(--atonco-primary) 100%) 1;\n    border-bottom: 1px solid var(--atonco-border);\n  }\n}\n\n.circle-icon {\n  width: 10px;\n  height: 10px;\n  min-width: 10px;\n  min-height: 10px;\n  max-width: 10px;\n  max-height: 10px;\n  border-radius: 50%;\n  background: var(--atonco-primary);\n  flex: 0 0 10px;\n  align-self: center;\n  box-shadow: 0 0 0 3px rgba(49,103,255,0.2);\n  display: block;\n}\n\n.circle-icon.secondary {\n  background: var(--atonco-secondary);\n  box-shadow: 0 0 0 3px rgba(58,224,106,0.2);\n}\n\n.atonco-underline {\n  height: 3px;\n  background: linear-gradient(90deg, var(--atonco-primary) 0%, #414d93 35%, var(--atonco-secondary) 70%, var(--atonco-primary) 100%);\n  width: 180px;\n  margin: 8px 0 32px;\n  border-radius: 2px;\n  box-shadow: 0 10px 30px rgba(0, 0, 0, .08);\n}\n\n.about-section-bg {\n  position: relative;\n  background: linear-gradient(180deg, #ffffff 0%, #f8faff 50%, var(--atonco-card) 100%);\n}\n\n.about-section-bg:before {\n  content: \"\";\n  position: absolute;\n  inset: 0;\n  background-image:\n    linear-gradient(to right, rgba(49,103,255,0.03) 1px, transparent 1px),\n    linear-gradient(to bottom, rgba(49,103,255,0.03) 1px, transparent 1px);\n  background-size: 48px 48px;\n  pointer-events: none;\n}\n\n.tech-section {\n  background: #ffffff;\n  padding: 4rem 2rem;\n}\n\n.tech-container {\n  max-width: 1280px;\n  margin: 0 auto;\n}\n\n.section-title {\n  font-size: 36px;\n  font-weight: 800;\n  color: #111827;\n  margin-bottom: 0.5rem;\n}\n\n.section-subtitle {\n  font-size: 20px;\n  color: #7a4aa0;\n  font-weight: 600;\n  margin-bottom: 2rem;\n}\n\n.gradient-line {\n  width: 4rem;\n  height: 0.25rem;\n  background: linear-gradient(90deg, #6B9BFF 0%, #7B8EC8 50%, #7DFFA8 100%);\n  margin-bottom: 2rem;\n}\n\n.content-text {\n  font-size: 16px;\n  line-height: 1.8;\n  color: #4b5563;\n  margin-bottom: 1.5rem;\n}\n\n.image-placeholder {\n  width: 100%;\n  height: 400px;\n  background: linear-gradient(135deg, #f3f4f6 0%, #e5e7eb 100%);\n  border-radius: 16px;\n  display: flex;\n  align-items: center;\n  justify-content: center;\n  color: #9ca3af;\n  font-size: 18px;\n  font-weight: 600;\n  box-shadow: 0 4px 12px rgba(0,0,0,0.08);\n  margin: 0;\n}\n\n.info-card-tech {\n  background: linear-gradient(135deg, rgba(107, 155, 255, 0.05) 0%, rgba(122, 74, 160, 0.05) 100%);\n  border-left: 4px solid #7a4aa0;\n  padding: 2rem;\n  border-radius: 12px;\n  margin: 2rem 0;\n}\n\n.biblio-section {\n  background: #f9fafb;\n  padding: 3rem 2rem;\n  border-radius: 16px;\n  margin-top: 3rem;\n}\n\n.biblio-title {\n  font-size: 24px;\n  font-weight: 700;\n  color: #111827;\n  margin-bottom: 1.5rem;\n  text-transform: uppercase;\n  letter-spacing: 0.05em;\n}\n\n.biblio-item {\n  font-size: 15px;\n  line-height: 1.7;\n  color: #4b5563;\n  margin-bottom: 1rem;\n  padding-left: 1.5rem;\n  position: relative;\n}\n\n.biblio-item:before {\n  content: \"\u2013\";\n  position: absolute;\n  left: 0;\n  color: #7a4aa0;\n  font-weight: 700;\n}\n\n.two-column-grid {\n  display: grid;\n  grid-template-columns: 1fr 1fr;\n  gap: 2rem;\n  margin: 2rem 0 1rem 0;\n  align-items: start;\n}\n\n\/* WordPress columns layout *\/\n.wp-block-columns {\n  display: flex;\n  flex-wrap: wrap;\n  gap: 1.5rem;\n  align-items: flex-start;\n  width: 100%;\n  box-sizing: border-box;\n}\n\n.wp-block-column {\n  flex-grow: 1;\n  min-width: 0;\n  box-sizing: border-box;\n  flex-basis: calc(50% - 0.75rem);\n}\n\n@media (max-width: 968px) {\n  .two-column-grid {\n    grid-template-columns: 1fr;\n    gap: 1.5rem;\n  }\n  .wp-block-column {\n    flex-basis: 100% !important;\n  }\n}\n<\/style>\n\n<nav class=\"atonco-submenu-nav\">\n  <div class=\"nav-container\">\n    <button class=\"atonco-tab-btn active\" data-tab=\"technologie\" onclick=\"switchTab('technologie')\">Technology<\/button>\n    <button class=\"atonco-tab-btn\" data-tab=\"vessie\" onclick=\"switchTab('vessie')\">Bladder Cancer<\/button>\n    <button class=\"atonco-tab-btn\" data-tab=\"at211\" onclick=\"switchTab('at211')\">Targeted Alpha Therapy At-211<\/button>\n  <\/div>\n<\/nav>\n\n\n<!-- TAB \"TECHNOLOGY\" -->\n\n<div id=\"tab-technologie\" class=\"atonco-tab-content active\">\n\n\n<!-- Targeted Alpha Therapy Section -->\n\n<div class=\"wp-block-group tech-section is-layout-flow wp-block-group-is-layout-flow\">\n  <div class=\"tech-container\">\n    \n    <!-- HEADER -->\n    <div class=\"wp-block-group\" style=\"margin-bottom:48px\">\n      \n      <div style=\"display:flex;align-items:center;gap:6px;color:var(--atonco-primary);font-size:0.78rem;font-weight:700;letter-spacing:0.12em;text-transform:uppercase;width:fit-content;margin-bottom:0;\">\n        <span style=\"display:block;width:10px;height:10px;min-width:10px;min-height:10px;border-radius:50%;background:var(--atonco-primary);box-shadow:0 0 0 3px rgba(49,103,255,0.2);flex:none;\"><\/span>\n        <span style=\"display:block;width:10px;height:10px;min-width:10px;min-height:10px;border-radius:50%;background:var(--atonco-secondary);box-shadow:0 0 0 3px rgba(58,224,106,0.2);flex:none;\"><\/span>\n        Technology\n      <\/div>\n      \n      \n      <div class=\"atonco-underline\"><\/div>\n      \n      \n      <h1 class=\"wp-block-heading has-text-color\" style=\"color:var(--atonco-ink);font-size:clamp(2.1rem,2.2rem + 1.6vw,3.25rem);font-weight:800;letter-spacing:-0.02em;line-height:1.1\">Therapeutic innovation<\/h1>\n      \n    <\/div>\n    \n    <p class=\"content-text\">The technology developed by Atonco is a <strong>highly promising disruptive innovation<\/strong> in the eradication of microscopic residual disease or isolated or clustered residual tumor cells that are rapidly accessible to a radiopharmaceutical labeled with astatine-211.<\/p>\n\n    <p class=\"content-text\">The use of alpha particle-emitting radionuclides is a current topic of great medical interest due to the <strong>high cytotoxic effect<\/strong> of these alpha particles on tumor cells, which results in double-strand DNA breaks. Furthermore, this approach offers good tolerability because the short range of alpha particles potentially spares normal tissues close to tumor targets.<\/p>\n\n    \n    <div class=\"two-column-grid\">\n      <div>\n        <img decoding=\"async\" src=\"https:\/\/atonco-pharma.com\/wp-content\/uploads\/2025\/10\/targeted-alpha-therapyEN.jpg\" alt=\"Targeted Alpha Therapy illustration\" style=\"border-radius:16px;box-shadow:0 4px 16px rgba(0,0,0,0.1);width:100%;height:auto;\"\/>\n      <\/div>\n      <div>\n        <img decoding=\"async\" src=\"https:\/\/atonco-pharma.com\/wp-content\/uploads\/2025\/10\/ATONCO-Technologie-ENGL.jpg\" alt=\"Mechanism of action\" style=\"border-radius:16px;box-shadow:0 4px 16px rgba(0,0,0,0.1);width:100%;height:auto;\"\/>\n      <\/div>\n    <\/div>\n    \n  <\/div>\n<\/div>\n\n\n<!-- Why Astatine-211 Section -->\n<div class=\"wp-block-group has-white-background-color has-background\" style=\"padding-top:4rem;padding-right:2rem;padding-bottom:4rem;padding-left:2rem\">\n  <div class=\"tech-container\">\n    \n    <h2 class=\"wp-block-heading has-text-color\" style=\"color:var(--atonco-ink);font-size:clamp(28px,3vw,36px);font-weight:700\">Why Astatine-211?<\/h2>\n\n    \n    <div class=\"gradient-line\"><\/div>\n    \n\n    \n    <div class=\"info-card-tech\">\n      <p style=\"font-size:17px;line-height:1.8;color:#374151;margin:0;\">\n        Astatine-211 (\u00b2\u00b9\u00b9At) represents the optimal alpha-emitting radionuclide for targeted therapy due to its unique physical and chemical properties. Its half-life of 7.2 hours offers an ideal balance between the time required for production, purification, conjugation, and therapeutic administration, while avoiding prolonged systemic exposure.\n      <\/p>\n    <\/div>\n    \n\n    <p class=\"content-text\">The alpha particles emitted by \u00b2\u00b9\u00b9At have an energy of 5.9 MeV with a tissue range of 55\u201380 \u03bcm, corresponding to 5\u201310 cell diameters. This characteristic enables selective destruction of targeted tumor cells while preserving adjacent healthy tissue, offering an exceptionally favorable therapeutic index.<\/p>\n\n    <p class=\"content-text\">The high linear energy transfer (LET) of ~100 keV\/\u03bcm induces irreparable DNA damage, independent of the oxygenation status of tumor cells. This property is particularly advantageous for the treatment of hypoxic tumors, which are often resistant to conventional therapies.<\/p>\n  <\/div>\n<\/div>\n\n<!-- Bibliography Section -->\n<div class=\"wp-block-group has-background\" style=\"background-color:#f9fafb;padding-top:4rem;padding-right:2rem;padding-bottom:4rem;padding-left:2rem\">\n  <div class=\"tech-container\">\n    \n    <div class=\"biblio-section\">\n      <h3 class=\"biblio-title\">Bibliography<\/h3>\n      <div class=\"biblio-item\">\n        Barbet J, Chatal JF. The best radionuclide for radioimmunotherapy of small tumors: beta- or alpha-emitters? <em>Eur J Nucl Med Mol Imaging<\/em> 2011;38:271-273. <a href=\"https:\/\/doi.org\/10.1007\/s00259-010-1707-7\" target=\"_blank\">DOI: 10.1007\/s00259-010-1707-7<\/a>\n      <\/div>\n      <div class=\"biblio-item\">\n        Chatal JF, Kraeber-Bod\u00e9r\u00e9 F, Cherel M, Haddad F. Alphatherapy, the new impetus to targeted radionuclide therapy. <em>European Journal of Nuclear Medicine and Molecular Imaging<\/em> 2018;45:1233\u20131234. <a href=\"https:\/\/doi.org\/10.1007\/s00259-018-4026-z\" target=\"_blank\">DOI: 10.1007\/s00259-018-4026-z<\/a>\n      <\/div>\n      <div class=\"biblio-item\">\n        Eychenne R, Ch\u00e9rel M, Haddad F, Gu\u00e9rard F, Gestin JF. Overview of the Most Promising Radionuclides for Targeted Alpha Therapy: The &#8220;Hopeful Eight&#8221;. <em>Pharmaceutics<\/em> 2021, 13, 906. <a href=\"https:\/\/doi.org\/10.3390\/pharmaceutics13060906\" target=\"_blank\">https:\/\/doi.org\/10.3390\/pharmaceutics13060906<\/a>\n      <\/div>\n    <\/div>\n    \n  <\/div>\n<\/div>\n\n\n<\/div>\n\n\n<!-- TAB \"BLADDER CANCER\" -->\n\n<div id=\"tab-vessie\" class=\"atonco-tab-content\">\n\n\n<!-- Bladder Cancer Section with image -->\n<div class=\"wp-block-group about-section-bg\" style=\"padding-top:4rem;padding-bottom:4rem;\">\n<div style=\"max-width:1280px;margin-left:auto;margin-right:auto;padding-left:2rem;padding-right:2rem;\">\n  \n  <!-- HEADER -->\n  <div class=\"wp-block-group\" style=\"margin-bottom:48px\">\n    \n    <div style=\"display:flex;align-items:center;gap:6px;color:var(--atonco-primary);font-size:0.78rem;font-weight:700;letter-spacing:0.12em;text-transform:uppercase;width:fit-content;margin-bottom:0;\">\n      <span style=\"display:block;width:10px;height:10px;min-width:10px;min-height:10px;border-radius:50%;background:var(--atonco-primary);box-shadow:0 0 0 3px rgba(49,103,255,0.2);flex:none;\"><\/span>\n      <span style=\"display:block;width:10px;height:10px;min-width:10px;min-height:10px;border-radius:50%;background:var(--atonco-secondary);box-shadow:0 0 0 3px rgba(58,224,106,0.2);flex:none;\"><\/span>\n      Bladder Cancer\n    <\/div>\n    \n    \n    <div class=\"atonco-underline\"><\/div>\n    \n    \n    <h1 class=\"wp-block-heading has-text-color\" style=\"color:var(--atonco-ink);font-size:clamp(2.1rem,2.2rem + 1.6vw,3.25rem);font-weight:800;letter-spacing:-0.02em;line-height:1.1\">Clinical application<\/h1>\n    \n  <\/div>\n  \n  <p class=\"has-text-color\" style=\"color:var(--atonco-primary);margin-bottom:1.5rem;font-size:1.15rem;font-weight:600;line-height:1.6\">Alpha-immunotherapy of non-muscle-invasive bladder cancer (NMIBC) with a chimeric anti-Carbonic Anhydrase IX (CAIX) antibody, girentuximab, labeled with astatine-211: our candidate, ATO-101\u2122<\/p>\n  \n  <p class=\"content-text\">ATO-101\u2122 targets non-muscle-invasive bladder tumors that are refractory to BCG and chemotherapy and pending total cystectomy.<\/p>\n  \n  <p class=\"content-text\">ATO-101\u2122, our radiopharmaceutical candidate, is an anti-CAIX antibody labeled with astatine-211 using a proprietary radiolabeling technology developed in Nantes, France.<\/p>\n  \n  <!-- SECTION 1: CAIX text + hologram image -->\n  <div class=\"wp-block-columns are-vertically-aligned-center\" style=\"margin-top:3rem;margin-bottom:3rem\">\n    \n    <div class=\"wp-block-column is-vertically-aligned-center\">\n      <p class=\"content-text\">The CAIX antigen is expressed on the membrane of cancer cells of superficial non-muscle-invasive bladder tumors and is therefore directly and rapidly accessible to the radiolabeled anti-CAIX antibody instilled intravesically. Furthermore, recurrences that frequently occur after repeated BCG or chemotherapy treatments consist of thin layers of cancer cells that respond well to the very short path length of the emitted alpha particles. Thus, the non-muscle-invasive bladder tumor setting is well suited to the radiophysical characteristics of alpha particles.<\/p>\n    <\/div>\n    \n    <div class=\"wp-block-column is-vertically-aligned-center\">\n      <figure class=\"wp-block-image size-large has-custom-border\">\n        <img decoding=\"async\" src=\"https:\/\/atonco-pharma.com\/wp-content\/uploads\/2025\/10\/vessie-hologramme.jpg\" alt=\"Bladder cancer\" style=\"border-radius:16px;box-shadow:0 4px 16px rgba(0,0,0,0.1);width:100%;height:auto;\"\/>\n      <\/figure>\n    <\/div>\n    \n  <\/div>\n  \n  <!-- SECTION 2: Bunny video + tumor text -->\n  <div class=\"wp-block-columns are-vertically-aligned-center\" style=\"margin-top:3rem;margin-bottom:3rem\">\n    \n    <div class=\"wp-block-column is-vertically-aligned-center\">\n      \n      <div style=\"position:relative;padding-top:56.25%;border-radius:12px;overflow:hidden;box-shadow:0 10px 30px rgba(0,0,0,0.15);\">\n        <iframe src=\"https:\/\/player.mediadelivery.net\/embed\/533463\/32e7da28-109c-4237-b755-a89b61e511f1\" loading=\"lazy\" style=\"border:none;position:absolute;top:0;left:0;height:100%;width:100%;\" allow=\"accelerometer;gyroscope;encrypted-media;picture-in-picture;\" allowfullscreen=\"true\"><\/iframe>\n      <\/div>\n      \n    <\/div>\n    \n    <div class=\"wp-block-column is-vertically-aligned-center\">\n      <p class=\"content-text\">The tumors have a thin thickness well suited to the very short path length (&lt;0.1 mm) of the alpha particles, and their superficial location in the bladder cavity makes them accessible to a radiopharmaceutical instilled intravesically. Moreover, the clinical situation of patients refractory to conventional BCG therapy or chemotherapy, for whom the risk of an uncomfortable total cystectomy justifies the implementation of the innovative alpha-immunotherapy delivered by intravesical instillation.<\/p>\n    <\/div>\n    \n  <\/div>\n\n<\/div>\n<\/div>\n\n<!-- Treatment History Section -->\n<div class=\"wp-block-group has-white-background-color has-background\" style=\"padding-top:4rem;padding-right:2rem;padding-bottom:4rem;padding-left:2rem\">\n  <div class=\"tech-container\">\n    \n    <h2 class=\"wp-block-heading has-text-color\" style=\"color:var(--atonco-primary);font-size:14px;font-weight:700;letter-spacing:0.1em;text-transform:uppercase\">History of bladder cancer treatments<\/h2>\n    \n    \n    <div class=\"gradient-line\" style=\"margin-bottom:2.5rem\"><\/div>\n    \n    \n    <figure class=\"wp-block-image\">\n      <img decoding=\"async\" src=\"https:\/\/atonco-pharma.com\/wp-content\/uploads\/2025\/10\/blader-therapy-history.png\" alt=\"Treatment history\" style=\"border-radius:16px;box-shadow:0 4px 16px rgba(0,0,0,0.1);width:100%;height:auto;\"\/>\n    <\/figure>\n    \n  <\/div>\n<\/div>\n\n<!-- Cancer Stages Section -->\n<div class=\"wp-block-group has-white-background-color has-background\" style=\"padding-top:4rem;padding-right:2rem;padding-bottom:4rem;padding-left:2rem\">\n  <div class=\"tech-container\">\n    \n    <h2 class=\"wp-block-heading has-text-color\" style=\"color:var(--atonco-primary);font-size:14px;font-weight:700;letter-spacing:0.1em;text-transform:uppercase\">Stages of bladder cancer<\/h2>\n    \n    \n    <div class=\"gradient-line\" style=\"margin-bottom:2.5rem\"><\/div>\n    \n    \n    <figure class=\"wp-block-image\">\n      <img decoding=\"async\" src=\"https:\/\/atonco-pharma.com\/wp-content\/uploads\/2025\/10\/bladder-cancer-stages.jpg\" alt=\"Stages of bladder cancer\" style=\"border-radius:16px;box-shadow:0 4px 16px rgba(0,0,0,0.1);width:100%;height:auto;\"\/>\n    <\/figure>\n    \n  <\/div>\n<\/div>\n\n<!-- Treatment - Intravesical Instillation Section -->\n<div class=\"wp-block-group has-white-background-color has-background\" style=\"padding-top:4rem;padding-right:2rem;padding-bottom:4rem;padding-left:2rem\">\n  <div class=\"tech-container\">\n    \n    <h2 class=\"wp-block-heading has-text-color\" style=\"color:var(--atonco-primary);font-size:14px;font-weight:700;letter-spacing:0.1em;text-transform:uppercase\">Treatment \u2013 Intravesical instillation<\/h2>\n    \n    \n    <div class=\"gradient-line\" style=\"margin-bottom:2.5rem\"><\/div>\n    \n    \n    <figure class=\"wp-block-image\">\n      <img decoding=\"async\" src=\"https:\/\/atonco-pharma.com\/wp-content\/uploads\/2025\/10\/traitement-instillationEN.jpg\" alt=\"Treatment by intravesical instillation\" style=\"border-radius:16px;box-shadow:0 4px 16px rgba(0,0,0,0.1);width:100%;height:auto;\"\/>\n    <\/figure>\n    \n  <\/div>\n<\/div>\n\n<!-- Bibliography Section -->\n<div class=\"wp-block-group has-background\" style=\"background-color:#f9fafb;padding-top:4rem;padding-right:2rem;padding-bottom:4rem;padding-left:2rem\">\n  <div class=\"tech-container\">\n    \n    <div class=\"biblio-section\">\n      <h3 class=\"biblio-title\">Bibliography<\/h3>\n      <div class=\"biblio-item\">\n        Pfost B, Seidl C, Autenrieth M, et al. Intravesical \u03b1-radioimmunotherapy with 213Bi-anti-EGFR-mAb defeats human bladder carcinoma in xenografted nude mice. <em>J Nucl Med<\/em> 2009;50:1700-1708. <a href=\"https:\/\/doi.org\/10.2967\/jnumed.109.065961\" target=\"_blank\">DOI: 10.2967\/jnumed.109.065961<\/a>\n      <\/div>\n      <div class=\"biblio-item\">\n        Autenrieth ME, Seidl C, Bruchertseifer F, et al. Treatment of carcinoma in situ of the urinary bladder with an alpha-emitter immunoconjugate targeting the epidermal growth factor receptor: a pilot study. <em>Eur J Nucl Med Mol Imaging<\/em> 2018;45:1364-1371. <a href=\"https:\/\/doi.org\/10.1007\/s00259-018-4003-6\" target=\"_blank\">DOI: 10.1007\/s00259-018-4003-6<\/a>\n      <\/div>\n      <div class=\"biblio-item\">\n        Rousseau C, Baumgartner P, Heymann MF, et al. Preclinical and Clinical Feasibility Studies as the First Step Before Forthcoming Intravesical Instillation of [\u00b2\u00b9\u00b9At]At-anti-CA-IX Antibody (ATO-101\u2122) Study in Patients with Non-Muscle-Invasive Bladder Cancer Unresponsive to Standard of Care. <em>Cancers<\/em> 2025;17(7):1190. <a href=\"https:\/\/doi.org\/10.3390\/cancers17071190\" target=\"_blank\">DOI: 10.3390\/cancers17071190<\/a>\n      <\/div>\n      <div class=\"biblio-item\">\n        Klatte T, Seligson DB, Rao JY, et al. Carbonic Anhydrase IX in Bladder Cancer. <em>Cancer<\/em> 2009;115(7):7. <a href=\"https:\/\/doi.org\/10.1002\/cncr.24163\" target=\"_blank\">DOI: 10.1002\/cncr.24163<\/a>\n      <\/div>\n      <div class=\"biblio-item\">\n        CAIX stratification-based cancer treatment, WO2014\/128258\n      <\/div>\n      <div class=\"biblio-item\">\n        Method for synthesizing iodo- or astatoarenes using diaryliodonium salts, WO2016\/EP78729\n      <\/div>\n      <div class=\"biblio-item\">\n        Novel radiolabelled antibodies, WO2025\/111661\n      <\/div>\n    <\/div>\n    \n  <\/div>\n<\/div>\n\n\n<\/div>\n\n\n<!-- TAB \"TARGETED ALPHA THERAPY AT-211\" -->\n\n<div id=\"tab-at211\" class=\"atonco-tab-content\">\n\n\n<div class=\"wp-block-group about-section-bg\" style=\"padding-top:5rem;padding-bottom:5rem;\">\n<div style=\"max-width:1280px;margin-left:auto;margin-right:auto;padding-left:2rem;padding-right:2rem;\">\n  \n  <!-- HEADER -->\n  <div class=\"wp-block-group\" style=\"margin-bottom:48px\">\n    \n    <div style=\"display:flex;align-items:center;gap:6px;color:var(--atonco-primary);font-size:0.78rem;font-weight:700;letter-spacing:0.12em;text-transform:uppercase;width:fit-content;margin-bottom:0;\">\n      <span style=\"display:block;width:10px;height:10px;min-width:10px;min-height:10px;border-radius:50%;background:var(--atonco-primary);box-shadow:0 0 0 3px rgba(49,103,255,0.2);flex:none;\"><\/span>\n      <span style=\"display:block;width:10px;height:10px;min-width:10px;min-height:10px;border-radius:50%;background:var(--atonco-secondary);box-shadow:0 0 0 3px rgba(58,224,106,0.2);flex:none;\"><\/span>\n      Targeted Alpha Therapy\n    <\/div>\n    \n    \n    <div class=\"atonco-underline\"><\/div>\n    \n    \n    <h1 class=\"wp-block-heading has-text-color\" style=\"color:var(--atonco-ink);font-size:clamp(2.1rem,2.2rem + 1.6vw,3.25rem);font-weight:800;letter-spacing:-0.02em;line-height:1.1\">Innovative treatment<\/h1>\n    \n  <\/div>\n  \n  <p class=\"content-text\" style=\"margin-top:2rem;margin-bottom:2rem\">Targeted alpha therapy using Astatine-211 represents a major advance in the treatment of cancer, offering decisive advantages over conventional therapeutic approaches.<\/p>\n  \n<\/div>\n<\/div>\n\n<!-- Advantages of Alpha Particles Section -->\n<div class=\"wp-block-group has-white-background-color has-background\" style=\"padding-top:4rem;padding-right:2rem;padding-bottom:4rem;padding-left:2rem\">\n  <div class=\"tech-container\">\n    \n    <h2 class=\"wp-block-heading has-text-color\" style=\"color:var(--atonco-ink);font-size:clamp(28px,3vw,36px);font-weight:700\">Advantages of alpha particles over conventional treatments<\/h2>\n\n    \n    <div class=\"gradient-line\"><\/div>\n    \n    \n    <p class=\"content-text\">Alpha particles offer decisive advantages in killing tumor cells compared to external radiotherapy and chemotherapy, notably through their superior biological efficacy and limited toxicity to surrounding healthy tissues. Their very high linear energy transfer (100 times greater than that of beta radiation\/electrons) induces irreparable double-strand DNA breaks, leading to irreversible destruction of cancer cells. Moreover, the very short range of alpha particles (only a few cell layers) concentrates the dose locally, reducing damage to nearby healthy cells and limiting the unwanted side effects often observed with external radiotherapy and chemotherapy.<\/p>\n\n    <h3 class=\"wp-block-heading has-text-color\" style=\"color:var(--atonco-primary);margin-top:3rem;margin-bottom:1.5rem;font-size:24px;font-weight:700\">Biological efficacy and mechanism of action<\/h3>\n\n    <p class=\"content-text\">Unlike treatments such as chemotherapy that require prolonged cellular internalization, targeted alpha therapy can kill tumor cells through the immediate damage caused by alpha particles to DNA without requiring internalization of the vector. One to three alpha particles are sufficient to kill a tumor cell, whereas thousands of beta particles or chemotherapy molecules are required. This targeted efficacy is particularly well suited to micro-metastases and small residual tumor clusters, as in the case of non-muscle-invasive bladder cancer following resection of macroscopic lesions.<\/p>\n\n    <h3 class=\"wp-block-heading has-text-color\" style=\"color:var(--atonco-primary);margin-top:3rem;margin-bottom:1.5rem;font-size:24px;font-weight:700\">Limited toxicity and precise targeting<\/h3>\n\n    <p class=\"content-text\">The short range of alpha particles in tissue (2 to 5 cell layers) allows a very local concentration of the dose, thereby reducing toxicity to surrounding healthy tissues, unlike more diffuse external radiotherapy or chemotherapy which can affect multiple cell types. This targeting is made possible through the use of biological vectors (antibodies, peptides) that carry the alpha radioisotope directly to tumor cells, reducing the area of exposure and systemic side effects.<\/p>\n\n    <h3 class=\"wp-block-heading has-text-color\" style=\"color:var(--atonco-primary);margin-top:3rem;margin-bottom:1.5rem;font-size:24px;font-weight:700\">Comparison with external radiotherapy and chemotherapy<\/h3>\n\n    \n    <div class=\"info-card-tech\">\n      <p style=\"font-size:16px;line-height:1.8;color:#374151;margin:0 0 1rem 0;\"><strong>External radiotherapy:<\/strong> often treats a broad tumor and surrounding area, thereby exposing healthy tissues to radiation and potentially causing significant side effects. Its wider penetration is less suited to small, dispersed lesions.<\/p>\n      \n      <p style=\"font-size:16px;line-height:1.8;color:#374151;margin:0 0 1rem 0;\"><strong>Chemotherapy:<\/strong> acts systemically, also affecting healthy cells with multiple toxicities, particularly hematological and gastrointestinal.<\/p>\n      \n      <p style=\"font-size:16px;line-height:1.8;color:#374151;margin:0;\"><strong>Alpha therapy:<\/strong> precisely targets cancer cells, minimizes collateral damage, and optimizes cell destruction even in difficult-to-reach areas such as micro-metastases.<\/p>\n    <\/div>\n    \n\n    <p class=\"content-text\" style=\"margin-top:2rem\">These advantages make alpha particle therapy a promising and complementary therapeutic approach, particularly in cancers resistant to conventional treatments, offering a better efficacy-to-toxicity ratio.<\/p>\n\n  <\/div>\n<\/div>\n\n\n<\/div>\n\n\n<!-- JAVASCRIPT FOR TABS -->\n\n<script>\nfunction switchTab(tabName) {\n  \/\/ Hide all content\n  document.querySelectorAll('.atonco-tab-content').forEach(function(content) {\n    content.classList.remove('active');\n  });\n\n  \/\/ Deactivate all buttons\n  document.querySelectorAll('.atonco-tab-btn').forEach(function(btn) {\n    btn.classList.remove('active');\n  });\n\n  \/\/ Activate selected content and button\n  document.getElementById('tab-' + tabName).classList.add('active');\n  document.querySelector('[data-tab=\"' + tabName + '\"]').classList.add('active');\n\n  \/\/ Update URL with hash\n  window.location.hash = tabName;\n\n  \/\/ Scroll to sub-menu\n  document.querySelector('.atonco-submenu-nav').scrollIntoView({ behavior: 'smooth', block: 'start' });\n}\n\n\/\/ On page load, check if a hash exists in the URL\nwindow.addEventListener('DOMContentLoaded', function() {\n  var hash = window.location.hash.substring(1);\n\n  if (hash && (hash === 'technologie' || hash === 'vessie' || hash === 'at211')) {\n    switchTab(hash);\n  }\n});\n\n\/\/ Listen for hash changes (browser back button)\nwindow.addEventListener('hashchange', function() {\n  var hash = window.location.hash.substring(1);\n\n  if (hash && (hash === 'technologie' || hash === 'vessie' || hash === 'at211')) {\n    switchTab(hash);\n  }\n});\n<\/script>\n","protected":false},"excerpt":{"rendered":"<p>Technology Bladder Cancer Targeted Alpha Therapy At-211 Why Astatine-211? Astatine-211 (\u00b2\u00b9\u00b9At) represents the optimal alpha-emitting radionuclide for targeted therapy due to its unique physical and chemical properties. Its half-life of 7.2 hours offers an ideal balance between the time required for production, purification, conjugation, and therapeutic administration, while avoiding prolonged systemic exposure. The alpha particles [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"pulsehome","meta":{"footnotes":""},"class_list":["post-1219","page","type-page","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Atonco Technology \u2013 Targeted Alpha Radiotherapy ATO-101\u2122<\/title>\n<meta name=\"description\" content=\"Discover Atonco&#039;s innovative technology: alpha-immunotherapy with astatine-211 to target residual tumor cells in bladder cancer.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/atonco-pharma.com\/en\/technology\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Atonco Technology \u2013 Targeted Alpha Radiotherapy ATO-101\u2122\" \/>\n<meta property=\"og:description\" content=\"Discover Atonco&#039;s innovative technology: alpha-immunotherapy with astatine-211 to target residual tumor cells in bladder cancer.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/atonco-pharma.com\/en\/technology\/\" \/>\n<meta property=\"og:site_name\" content=\"Atonco\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-31T11:42:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/atonco-pharma.com\/wp-content\/uploads\/2025\/10\/contact2.jpg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/technology\\\/\",\"url\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/technology\\\/\",\"name\":\"Atonco Technology \u2013 Targeted Alpha Radiotherapy ATO-101\u2122\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/technology\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/technology\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/atonco-pharma.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/contact2.jpg\",\"datePublished\":\"2025-10-21T19:32:43+00:00\",\"dateModified\":\"2026-03-31T11:42:21+00:00\",\"description\":\"Discover Atonco's innovative technology: alpha-immunotherapy with astatine-211 to target residual tumor cells in bladder cancer.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/technology\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/technology\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/technology\\\/#primaryimage\",\"url\":\"https:\\\/\\\/atonco-pharma.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/contact2.jpg\",\"contentUrl\":\"https:\\\/\\\/atonco-pharma.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/contact2.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/technology\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Technology\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/\",\"name\":\"Atonco\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/atonco-pharma.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Atonco Technology \u2013 Targeted Alpha Radiotherapy ATO-101\u2122","description":"Discover Atonco's innovative technology: alpha-immunotherapy with astatine-211 to target residual tumor cells in bladder cancer.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/atonco-pharma.com\/en\/technology\/","og_locale":"en_US","og_type":"article","og_title":"Atonco Technology \u2013 Targeted Alpha Radiotherapy ATO-101\u2122","og_description":"Discover Atonco's innovative technology: alpha-immunotherapy with astatine-211 to target residual tumor cells in bladder cancer.","og_url":"https:\/\/atonco-pharma.com\/en\/technology\/","og_site_name":"Atonco","article_modified_time":"2026-03-31T11:42:21+00:00","og_image":[{"url":"https:\/\/atonco-pharma.com\/wp-content\/uploads\/2025\/10\/contact2.jpg","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/atonco-pharma.com\/en\/technology\/","url":"https:\/\/atonco-pharma.com\/en\/technology\/","name":"Atonco Technology \u2013 Targeted Alpha Radiotherapy ATO-101\u2122","isPartOf":{"@id":"https:\/\/atonco-pharma.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/atonco-pharma.com\/en\/technology\/#primaryimage"},"image":{"@id":"https:\/\/atonco-pharma.com\/en\/technology\/#primaryimage"},"thumbnailUrl":"https:\/\/atonco-pharma.com\/wp-content\/uploads\/2025\/10\/contact2.jpg","datePublished":"2025-10-21T19:32:43+00:00","dateModified":"2026-03-31T11:42:21+00:00","description":"Discover Atonco's innovative technology: alpha-immunotherapy with astatine-211 to target residual tumor cells in bladder cancer.","breadcrumb":{"@id":"https:\/\/atonco-pharma.com\/en\/technology\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/atonco-pharma.com\/en\/technology\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/atonco-pharma.com\/en\/technology\/#primaryimage","url":"https:\/\/atonco-pharma.com\/wp-content\/uploads\/2025\/10\/contact2.jpg","contentUrl":"https:\/\/atonco-pharma.com\/wp-content\/uploads\/2025\/10\/contact2.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/atonco-pharma.com\/en\/technology\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/atonco-pharma.com\/en\/"},{"@type":"ListItem","position":2,"name":"Technology"}]},{"@type":"WebSite","@id":"https:\/\/atonco-pharma.com\/en\/#website","url":"https:\/\/atonco-pharma.com\/en\/","name":"Atonco","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/atonco-pharma.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/atonco-pharma.com\/en\/wp-json\/wp\/v2\/pages\/1219","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/atonco-pharma.com\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/atonco-pharma.com\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/atonco-pharma.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/atonco-pharma.com\/en\/wp-json\/wp\/v2\/comments?post=1219"}],"version-history":[{"count":12,"href":"https:\/\/atonco-pharma.com\/en\/wp-json\/wp\/v2\/pages\/1219\/revisions"}],"predecessor-version":[{"id":1336,"href":"https:\/\/atonco-pharma.com\/en\/wp-json\/wp\/v2\/pages\/1219\/revisions\/1336"}],"wp:attachment":[{"href":"https:\/\/atonco-pharma.com\/en\/wp-json\/wp\/v2\/media?parent=1219"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}